RPL22 and gastric cancer: By exploring human cancer databases available in cBioPortal (Supplementary Figure 1) [23, 24], we found that in addition to in endometrial and colorectal tumors (∼5%-12%), RPL22/eL22 is also highly mutated in stomach cancer (∼8%-13%) and a pool of cancer cell lines (Cancer Cell Line Encyclopedia, CCLE, Novartis/Broad, ∼7%) (Figure 1A).